Every 10-Q that Korro Bio, Inc. (KRRO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow KRRO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KRRO filings page.
Korro Bio, an RNA‑editing biopharma, reported no collaboration revenue for the three or six months ended June 30, 2026, versus $1,460 thousand and $4,010 thousand a year earlier, reflecting a 12‑month pause of its Novo Nordisk partnership. Net loss narrowed to $18,916 thousand for the quarter and $38,541 thousand for the first half, driven mainly by lower research and development spending.
Research and development expense fell to $26,539 thousand for the first half of 2026 from $39,874 thousand, and general and administrative expense declined to $14,007 thousand. The company strengthened liquidity through a March 2026 private placement (approximately $85.0 million gross) and January 2026 at‑the‑market sales ($5.1 million gross). Cash, cash equivalents and marketable securities totaled $137.9 million at June 30, 2026, which management expects to fund operations for at least 12 months.
Korro advanced lead programs KRRO‑121 for hyperammonemia, expected to enter first‑in‑human trials in the second half of 2026, and KRRO‑111 for alpha‑1 antitrypsin deficiency, after terminating the Phase 1/2a REWRITE trial for prior candidate KRRO‑110 in early 2026.
Korro Bio, Inc. reported a net loss of $19.6 million for the quarter ended March 31, 2026, improving from a $23.4 million loss a year earlier, as research and development and general and administrative costs declined. Collaboration revenue from Novo Nordisk fell to zero after a 12‑month pause of that agreement. Cash, cash equivalents and marketable securities rose to $157.1 million, driven by a March 2026 private placement and at‑the‑market share sales. The company expects this liquidity to fund operations into the second half of 2028 while advancing its OPERA RNA‑editing platform and lead program KRRO‑121 toward first‑in‑human studies.
Korro Bio reported clinical progress alongside continued cash burn. The company recognized $4.0 million of collaboration revenue from Novo Nordisk and reported dosing of first participants in its Phase 1/2a REWRITE trial of KRRO-110 for Alpha-1 Antitrypsin Deficiency, with interim single-ascending dose data expected in the second half of 2025 and orphan drug designations from the FDA and EMA. As of June 30, 2025 the company held $119.6 million of cash, cash equivalents and marketable securities, which management expects will fund operations into 2027.
However, losses remain significant: net loss was $49.2 million for the six months ended June 30, 2025 and the accumulated deficit was $315.7 million. Management executed a 19% workforce reduction and recorded severance charges. The balance sheet shows total assets of $180.4 million and operating lease liabilities with a present value of $44.6 million. The company states additional financing may be required to continue development.